Advanced Cell Therapy Centre, Finnish Red Cross Blood Service, Helsinki, Finland.
Front Immunol. 2019 Jul 16;10:1627. doi: 10.3389/fimmu.2019.01627. eCollection 2019.
Some recent reports suggest that cryopreserved and thawed mesenchymal stromal cells (MSCs) may have impaired functional properties as compared to freshly harvested MSCs from continuous cultures. A cryopreservation step in the manufacturing process brings important benefits, since it enables immediate off-the-shelf access to the products and a completion of all quality testing before batch release and administration to the patient. Cryopreservation is also inevitable in MSC banking strategies. In this study, we present the results from the MSC stability testing program of our in-house manufactured clinical-grade allogeneic bone marrow-derived MSC product that is expanded in platelet lysate and frozen in passage 2. The current manufacturing protocol contains only one freezing step and the frozen MSC product is thawed bed-side at the clinic. We can conclude superior viability and cell recovery of the frozen and thawed MSC product utilizing the validated freezing and thawing protocols we have developed. The MSC phenotype and differentiation potential was generally found to be unaltered after thawing, but the thawed cells exhibited a 50% reduced, but not completely abolished, performance in an immunosuppression assay. The immunosuppression assay results should, however, be interpreted with caution, since the chosen assay mainly measures one specific immunosuppressive mechanism of MSCs to suppress T-cell proliferation. Since at least two freezing steps are usually necessary in MSC banking strategies, we went on to investigate the impact of repeated freezing on MSC quality attributes. We can conclude that two freezing steps with a preceding cell culture phase of at least one passage before freezing is feasible and does not substantially affect basic cell manufacturing parameters or quality attributes of the final frozen and thawed product. Our results suggest, however, that an exhaustive number of freezing steps (≥4) may induce earlier senescence. In conclusion, our results support the utilization of frozen MSC products and MSC banking strategies, but emphasize the need of always performing detailed studies on also the cryopreserved MSC counterpart and to carefully report the cryopreservation and thawing protocols.
一些最新的报告表明,与连续培养中新鲜收获的间充质基质细胞 (MSC) 相比,冷冻保存和解冻的 MSC 可能具有受损的功能特性。在制造过程中进行冷冻保存步骤带来了重要的好处,因为它使产品能够立即随时使用,并在批量放行和给患者给药之前完成所有质量测试。MSC 储存策略中也不可避免地需要进行冷冻保存。在这项研究中,我们介绍了我们内部制造的临床级同种异体骨髓来源 MSC 产品的 MSC 稳定性测试计划的结果,该产品在血小板裂解物中扩增并在第 2 代冷冻。目前的制造方案仅包含一个冷冻步骤,冷冻的 MSC 产品在诊所床边解冻。我们可以得出结论,利用我们开发的经过验证的冷冻和解冻方案,冷冻和解冻的 MSC 产品具有更高的存活率和细胞回收率。解冻后,MSC 的表型和分化潜力通常未改变,但解冻后的细胞在免疫抑制测定中表现出 50%的降低,但并未完全消除其功能。然而,应该谨慎解释免疫抑制测定结果,因为所选测定主要测量 MSC 抑制 T 细胞增殖的一种特定免疫抑制机制。由于 MSC 储存策略中通常需要至少两个冷冻步骤,我们继续研究重复冷冻对 MSC 质量属性的影响。我们可以得出结论,至少进行两个冷冻步骤,并且在冷冻之前进行至少一个传代的细胞培养阶段是可行的,并且不会对基本细胞制造参数或最终冷冻和解冻产品的质量属性产生重大影响。然而,我们的结果表明,过多的冷冻步骤(≥4 个)可能会导致更早的衰老。总之,我们的结果支持使用冷冻 MSC 产品和 MSC 储存策略,但强调需要始终对冷冻 MSC 对照物进行详细研究,并仔细报告冷冻和解冻方案。